New drug against lung cancer and extraction separation method of new drug

Abstract

The invention discloses a new drug against lung cancer and an extraction separation method of the new drug. The extraction separation method comprises the following steps of: performing homogenate, 70% alcohol extraction, deproteinization by trichloroacetic acid and vacuum freeze-drying on whole mollusk Vaginulus alteFerussac, performing chromatographic separation by gel columns repeatedly for multiple times, detecting molecular weight, molecular organization and primary molecular structures of the components, and conducting in-vivo and vitro anticancer pharmacology experiments to obtain an anti-lung-cancer active ingredient JK of the Vaginulus alteFerussac. Animal experiments prove that the heavy inhibition ratio of the JK on human-derived lung adenocarcinoma A549 cytoma reaches 54.37%; the heavy inhibition ratio of the JK on human-derived small cell lung cancer CNI-H446 cytoma reaches 59.73%; the heavy inhibition ratio of the JK on rat-derived Lewis lung cancer tumor reaches 49.49%; and the combination of the JK and cinobufotalin generates a synergistic effect. The experiments also prove that the JK has anticancer mechanisms shared by multiple Chinese traditional medicines, is compound with multiple target points, and relates to the synthesis of nucleic acid for inhibiting lung cancer cells, induction of lung cancer apoptosis, angiogenesis for restraining lung cancer tissue and the adhesion of the cancer cells on a vascular wall after the cancer cells invade blood circulation.

Description

[0001] Technical Field: Biotechnology Background technique: [0002] At present, lung cancer is the first malignant tumor, with 1.2 million new lung cancers every year in the world; lung cancer is the most lethal, accounting for 17.8% of cancer deaths; lung cancer accounts for 15.19% of cancers in our country; 160 to 160 new cancer patients are added every year in our country 1.7 million people, about 4.5 million people in total; about 900,000 people have lung cancer; the 5-year survival period of lung cancer does not exceed 15%; the average survival period does not exceed two years. Lung cancer is a serious threat to people's life and health. The main method for the current treatment of lung cancer: surgery is the first choice, but 70-80% of newly discovered lung cancer patients are in the middle and late stage, and the chance of surgery has been lost. Radiotherapy is only effective for solitary tumors below 5 cm; chemotherapy, severe cytotoxicity, severe damage to liver, ki...

AI Technical Summary

Problems solved by technology

As early as 1997, he applied for the patent "Compound Slug and Its Preparation Method" (Application No. 97107941.2), and then gave up due to lack of funds for implementation; in 2004, he applied for the patent "Treatment of Lung Cancer, Chronic Bronchitis and Bronchial Asthma", (Application No. 200410026842.0) was automatically abandoned due to the lack of specificity of indications and complicated indicators of clinical observation effects; in 2005, the third patent "Slug PE4 Glycoprotein and Its Production Technology" was declared after in vitro and preliminary animal experiments. (Application No. 200510101458.7), the patent had to be withdrawn due to the discovery of heterosexual protein allergic reactions in subsequent experiments; in 2006, PE4 glycoprotein was deproteinized and applied for the patent of "Slug Polysaccharide and Production Technology", (Application No. 200610036736 .X), the content of the patented invention does have a good curative effect on lung cancer, but because the polysaccharide composition is not clarified, the active ingredients are unclear, and it is difficult to become a drug in the new drug application

It was withdrawn in order to save patent costs; in 2008, more in-depth research was carried out on slug polysaccharides, and the fifth patent "a kind of dextran" (application number 200810028974.5) was declared. Repeated extraction and separation experiments show that the purity of this dextran is too low, accounting for only 18.9-19.8% of the effective anti-lung cancer samples. It cannot be proved that this dextran is the main component of anti-lung cancer, so it lacks practical value

Images